Halozyme completes $1.5 billion convertible notes sale, repays 2027 and 2028 notes
Halozyme completed the sale of $1,500.0 million of convertible senior notes due 2031 and 2032, with net proceeds of about $1.47 billion. The company used part of the proceeds to repurchase existing convertible notes for about $1.020 billion in cash and to fund about $182.7 million of capped call transactions, with the remainder for general corporate purposes.
Key points
- Total principal of $1,500.0 million: $750.0 million of 0% notes due 2031 and $750.0 million of 0.875% notes due 2032, including $100.0 million of each from the initial purchasers' option
- Net proceeds of about $1.47 billion; about $1.020 billion paid in cash to repurchase 0.25% notes due 2027 and 1.00% notes due 2028, including accrued interest
- Initial conversion price of about $87.20 per share; the 2032 notes pay interest semi-annually at 0.875% beginning May 15, 2026
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 12, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.